Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: A Children's Oncology Group report

British Journal of Haematology

Volumn 162, Issue 5, 2013, Pages 678-683

  Barth, Matthew J ^a   Goldman, Stanton ^b   Smith, Lynette ^c   Perkins, Sherrie ^d   Shiramizu, Bruce ^e   Gross, Thomas G ^f   Harrison, Lauren ^g   Sanger, Warren ^h   Geyer, Mark B ⁱ   Giulino Roth, Lisa ^j,k   Cairo, Mitchell S ^g  

^a UNIVERSITY AT BUFFALO   (United States)

^b Medical City Children's Hospital   (United States)

^c UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF HAWAII   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g NEW YORK MEDICAL COLLEGE   (United States)

^h UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j WEILL CORNELL MEDICAL COLLEGE   (United States)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

CD20; Non Hodgkin lymphoma; Pediatric; Pharmacokinetics; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADOLESCENT; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; HUMAN; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PILOT STUDY; PRIORITY JOURNAL;

CD20; NON-HODGKIN LYMPHOMA; PEDIATRIC; PHARMACOKINETICS; RITUXIMAB;

ADOLESCENT; ADULT; AGE FACTORS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; HALF-LIFE; HUMANS; L-LACTATE DEHYDROGENASE; LYMPHOMA, B-CELL; METHOTREXATE; NEOPLASM STAGING; PILOT PROJECTS; PREDNISONE; VINCRISTINE; YOUNG ADULT;

EID: 84881663487     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12434     Document Type: Article

References (14)

1. Bennett, C.M., Rogers, Z.R., Kinnamon, D.D., Bussel, J.B., Mahoney, D.H., Abshire, T.C., Sawaf, H., Moore, T.B., Loh, M.L., Glader, B.E., McCarthy, M.C., Mueller, B.U., Olson, T.A., Lorenzana, A.N., Mentzer, W.C., Buchanan, G.R., Feldman, H.A. & Neufeld, E.J. (2006) Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood, 107, 2639-2642.
2. Cairo, M.S., Gerrard, M., Sposto, R., Auperin, A., Pinkerton, C.R., Michon, J., Weston, C., Perkins, S.L., Raphael, M., McCarthy, K. & Patte, C. (2007) Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood, 109, 2736-2743.
3. Cairo, M., Lynch, J., Harrison, L., Perkins, S., Shiramizu, B., Gross, T., Sanger, W. & Goldman, S. (2010) Safety, kinetics, and outcome following rituximab (R) in combination with FAB chemotherapy in children and adolescents (C+A) with stage III/IV (Group B) and BM+/CNS+ (Group C) mature B-NHL: a Children's Oncology Group report. Journal of Clinical Oncology, 28, (suppl; abstract 9536).
4. Cairo, M.S., Sposto, R., Gerrard, M., Auperin, A., Goldman, S.C., Harrison, L., Pinkerton, R., Raphael, M., McCarthy, K., Perkins, S.L. & Patte, C. (2012) Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study. Journal of Clinical Oncology, 30, 387-393.
5. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. The New England Journal of Medicine, 346, 235-242.
6. Dayde, D., Ternant, D., Ohresser, M., Lerondel, S., Pesnel, S., Watier, H., Le Pape, A., Bardos, P., Paintaud, G. & Cartron, G. (2009) Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood, 113, 3765-3772.
7. Goldman, S., Smith, L., Anderson, J.R., Perkins, S., Harrison, L., Geyer, M.B., Gross, T.G., Weinstein, H., Bergeron, S., Shiramizu, B., Sanger, W., Barth, M., Zhi, J. & Cairo, M.S. (2012) Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. Leukemia, 27, 1174-1177.
8. Jager, U., Fridrik, M., Zeitlinger, M., Heintel, D., Hopfinger, G., Burgstaller, S., Mannhalter, C., Oberaigner, W., Porpaczy, E., Skrabs, C., Einberger, C., Drach, J., Raderer, M., Gaiger, A., Putman, M. & Greil, R. (2012) Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica, 97, 1431-1438.
9. Maloney, D.G., Grillo-Lopez, A.J., White, C.A., Bodkin, D., Schilder, R.J., Neidhart, J.A., Janakiraman, N., Foon, K.A., Liles, T.M., Dallaire, B.K., Wey, K., Royston, I., Davis, T. & Levy, R. (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood, 90, 2188-2195.
10. Meinhardt, A., Burkhardt, B., Zimmermann, M., Borkhardt, A., Kontny, U., Klingebiel, T., Berthold, F., Janka-Schaub, G., Klein, C., Kabickova, E., Klapper, W., Attarbaschi, A., Schrappe, M. & Reiter, A. (2010) Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. Journal of Clinical Oncology, 28, 3115-3121.
11. Patte, C., Auperin, A., Gerrard, M., Michon, J., Pinkerton, R., Sposto, R., Weston, C., Raphael, M., Perkins, S.L., McCarthy, K. & Cairo, M.S. (2007) Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood, 109, 2773-2780.
12. Perkins, S.L., Lones, M.A., Davenport, V. & Cairo, M.S. (2003) B-Cell non-Hodgkin's lymphoma in children and adolescents: surface antigen expression and clinical implications for future targeted bioimmune therapy: a children's cancer group report. Clinical Advances in Hematology & Oncology, 1, 314-317.
13. Pranzatelli, M.R., Tate, E.D., Verhulst, S.J., Bertolone, S.J., Bhatla, D., Granger, M., Lebowizc, J., Lockhart, S.K. & Wiley, J.M. (2010) Pediatric dosing of rituximab revisited: serum concentrations in opsoclonus-myoclonus syndrome. Journal of Pediatric Hematology/Oncology, 32, e167-e172.
14. Tobinai, K., Kobayashi, Y., Narabayashi, M., Ogura, M., Kagami, Y., Morishima, Y., Ohtsu, T., Igarashi, T., Sasaki, Y., Kinoshita, T. & Murate, T. (1998) Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Annals of Oncology, 9, 527-534.